2006 Update of recommendations for the use of white blood cell growth factors

An evidence-based clinical practice guideline

Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, George Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn & 2 others Antoinette J. Wozniak, Antonio C. Wolff

Research output: Contribution to journalReview article

1336 Citations (Scopus)

Abstract

Purpose: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). Update Methodology: The Update Committee completed a review and analysis of pertinent data published from 1999 through September 2005. Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness. Recommendations: The 2005 Update Committee agreed unanimously that reduction in febrile neutropenia (FN) is an important clinical outcome that justifies the use of CSFs, regardless of impact on other factors, when the risk of FN is approximately 20% and no other equally effective regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of FN in patients who are at high risk based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. CSF use allows a modest to moderate increase in dose-density and/or dose-intensity of chemotherapy regimens. Dose-dense regimens should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Prophylactic CSF for patients with diffuse aggressive lymphoma aged 65 years and older treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of FN and infections. Current recommendations for the management of patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs, includes the prompt administration of CSF or pegylated G-CSF.

Original languageEnglish (US)
Pages (from-to)3187-3205
Number of pages19
JournalJournal of Clinical Oncology
Volume24
Issue number19
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Colony-Stimulating Factors
Evidence-Based Practice
Febrile Neutropenia
Practice Guidelines
Intercellular Signaling Peptides and Proteins
Leukocytes
Drug Therapy
Non-Hodgkin's Lymphoma
Cost-Benefit Analysis
Radiotherapy
Quality of Life
Clinical Trials
Guidelines
Survival
Incidence
Wounds and Injuries
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., ... Wolff, A. C. (2006). 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. Journal of Clinical Oncology, 24(19), 3187-3205. https://doi.org/10.1200/JCO.2006.06.4451

2006 Update of recommendations for the use of white blood cell growth factors : An evidence-based clinical practice guideline. / Smith, Thomas J.; Khatcheressian, James; Lyman, Gary H.; Ozer, Howard; Armitage, James O.; Balducci, Lodovico; Bennett, Charles L.; Cantor, Scott B.; Crawford, Jeffrey; Cross, Scott J.; Demetri, George; Desch, Christopher E.; Pizzo, Philip A.; Schiffer, Charles A.; Schwartzberg, Lee; Somerfield, Mark R.; Somlo, George; Wade, James C.; Wade, James L.; Winn, Rodger J.; Wozniak, Antoinette J.; Wolff, Antonio C.

In: Journal of Clinical Oncology, Vol. 24, No. 19, 01.07.2006, p. 3187-3205.

Research output: Contribution to journalReview article

Smith, TJ, Khatcheressian, J, Lyman, GH, Ozer, H, Armitage, JO, Balducci, L, Bennett, CL, Cantor, SB, Crawford, J, Cross, SJ, Demetri, G, Desch, CE, Pizzo, PA, Schiffer, CA, Schwartzberg, L, Somerfield, MR, Somlo, G, Wade, JC, Wade, JL, Winn, RJ, Wozniak, AJ & Wolff, AC 2006, '2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline', Journal of Clinical Oncology, vol. 24, no. 19, pp. 3187-3205. https://doi.org/10.1200/JCO.2006.06.4451
Smith, Thomas J. ; Khatcheressian, James ; Lyman, Gary H. ; Ozer, Howard ; Armitage, James O. ; Balducci, Lodovico ; Bennett, Charles L. ; Cantor, Scott B. ; Crawford, Jeffrey ; Cross, Scott J. ; Demetri, George ; Desch, Christopher E. ; Pizzo, Philip A. ; Schiffer, Charles A. ; Schwartzberg, Lee ; Somerfield, Mark R. ; Somlo, George ; Wade, James C. ; Wade, James L. ; Winn, Rodger J. ; Wozniak, Antoinette J. ; Wolff, Antonio C. / 2006 Update of recommendations for the use of white blood cell growth factors : An evidence-based clinical practice guideline. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 19. pp. 3187-3205.
@article{f3f3df2ac1de4cde988a469e4b6a3af6,
title = "2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline",
abstract = "Purpose: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). Update Methodology: The Update Committee completed a review and analysis of pertinent data published from 1999 through September 2005. Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness. Recommendations: The 2005 Update Committee agreed unanimously that reduction in febrile neutropenia (FN) is an important clinical outcome that justifies the use of CSFs, regardless of impact on other factors, when the risk of FN is approximately 20{\%} and no other equally effective regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of FN in patients who are at high risk based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. CSF use allows a modest to moderate increase in dose-density and/or dose-intensity of chemotherapy regimens. Dose-dense regimens should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Prophylactic CSF for patients with diffuse aggressive lymphoma aged 65 years and older treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of FN and infections. Current recommendations for the management of patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs, includes the prompt administration of CSF or pegylated G-CSF.",
author = "Smith, {Thomas J.} and James Khatcheressian and Lyman, {Gary H.} and Howard Ozer and Armitage, {James O.} and Lodovico Balducci and Bennett, {Charles L.} and Cantor, {Scott B.} and Jeffrey Crawford and Cross, {Scott J.} and George Demetri and Desch, {Christopher E.} and Pizzo, {Philip A.} and Schiffer, {Charles A.} and Lee Schwartzberg and Somerfield, {Mark R.} and George Somlo and Wade, {James C.} and Wade, {James L.} and Winn, {Rodger J.} and Wozniak, {Antoinette J.} and Wolff, {Antonio C.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1200/JCO.2006.06.4451",
language = "English (US)",
volume = "24",
pages = "3187--3205",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - 2006 Update of recommendations for the use of white blood cell growth factors

T2 - An evidence-based clinical practice guideline

AU - Smith, Thomas J.

AU - Khatcheressian, James

AU - Lyman, Gary H.

AU - Ozer, Howard

AU - Armitage, James O.

AU - Balducci, Lodovico

AU - Bennett, Charles L.

AU - Cantor, Scott B.

AU - Crawford, Jeffrey

AU - Cross, Scott J.

AU - Demetri, George

AU - Desch, Christopher E.

AU - Pizzo, Philip A.

AU - Schiffer, Charles A.

AU - Schwartzberg, Lee

AU - Somerfield, Mark R.

AU - Somlo, George

AU - Wade, James C.

AU - Wade, James L.

AU - Winn, Rodger J.

AU - Wozniak, Antoinette J.

AU - Wolff, Antonio C.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Purpose: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). Update Methodology: The Update Committee completed a review and analysis of pertinent data published from 1999 through September 2005. Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness. Recommendations: The 2005 Update Committee agreed unanimously that reduction in febrile neutropenia (FN) is an important clinical outcome that justifies the use of CSFs, regardless of impact on other factors, when the risk of FN is approximately 20% and no other equally effective regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of FN in patients who are at high risk based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. CSF use allows a modest to moderate increase in dose-density and/or dose-intensity of chemotherapy regimens. Dose-dense regimens should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Prophylactic CSF for patients with diffuse aggressive lymphoma aged 65 years and older treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of FN and infections. Current recommendations for the management of patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs, includes the prompt administration of CSF or pegylated G-CSF.

AB - Purpose: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). Update Methodology: The Update Committee completed a review and analysis of pertinent data published from 1999 through September 2005. Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness. Recommendations: The 2005 Update Committee agreed unanimously that reduction in febrile neutropenia (FN) is an important clinical outcome that justifies the use of CSFs, regardless of impact on other factors, when the risk of FN is approximately 20% and no other equally effective regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of FN in patients who are at high risk based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. CSF use allows a modest to moderate increase in dose-density and/or dose-intensity of chemotherapy regimens. Dose-dense regimens should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Prophylactic CSF for patients with diffuse aggressive lymphoma aged 65 years and older treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of FN and infections. Current recommendations for the management of patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs, includes the prompt administration of CSF or pegylated G-CSF.

UR - http://www.scopus.com/inward/record.url?scp=33745989223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745989223&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.06.4451

DO - 10.1200/JCO.2006.06.4451

M3 - Review article

VL - 24

SP - 3187

EP - 3205

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -